Newly Developing IgM Anti-GD1a/GD1b Ganglioside IgM Monoclonal Gammopathy in a Patient With Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

TitleNewly Developing IgM Anti-GD1a/GD1b Ganglioside IgM Monoclonal Gammopathy in a Patient With Chronic Inflammatory Demyelinating Polyradiculoneuropathy.
Publication TypeJournal Article
Year of Publication2026
AuthorsRoss RF, Langsdorf JA, Latov N
JournalJ Peripher Nerv Syst
Volume31
Issue4
Paginatione70174
Date Published2026 Dec
ISSN1529-8027
KeywordsAutoantibodies, Gangliosides, Humans, Immunoglobulin M, Male, Paraproteinemias, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Abstract

BACKGROUND AND AIMS: Chronic inflammatory demyelinating neuropathy (CIDP) is a rare, immune-mediated neuropathy that is distinct from other immune-mediated, paraneoplastic, and paraproteinemic neuropathies that may have overlapping clinical features. Identification of the specific diagnosis in each patient is important as each of these disorders has distinct pathophysiology and treatment response.

CASE REPORT: Here, we present an atypical case of CIDP in which the patient developed an IgM monoclonal gammopathy with positive anti-ganglioside antibodies over 20 years into his disease course.

INTERPRETATION: Patients with CIDP may be predisposed to develop IgM autoantibodies or monoclonal gammopathies. If a patient with CIDP experiences clinical worsening while on maintenance therapy, it may be helpful to test for anti-ganglioside antibodies and monoclonal gammopathies and reassess if alternative treatment would be useful.

DOI10.1111/jns.70174
Alternate JournalJ Peripher Nerv Syst
PubMed ID42785742

Weill Cornell Medicine Neurology 525 E. 68th St.
PO Box 117
New York, NY 10065 Phone: (212) 746-6575